Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.

Loading...
Thumbnail Image

Date

2019-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

76
views
234
downloads

Citation Stats

Abstract

In clinical trials, where the outcome of interest is the occurrence of an event over a fixed time period, estimation of the event proportion at interim analysis can form a basis for decision-making such as early trial termination, sample size re-estimation, and/or dropping inferior treatment arms. In addition to derivation of mean squared error under an exponential time-to-event distribution, we performed a simulation study to examine the performance of five estimators of the event proportion when time to the event is assessable. The simulation results showed advantages of the Kaplan-Meier estimator over others in terms of robustness, and the bias and variability of the event proportion estimate. An example was given to illustrate how the estimators affect dropping treatment arms in a multi-arm multi-stage adaptive trial. We recommended the use of the Kaplan-Meier estimator and discourage the use of other estimators that discard the inherent time-to-event information.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1080/10543406.2018.1559852

Publication Info

Lu, Qing Shu, Shein-Chung Chow and Siu-Keung Tse (2019). Interim analysis of binary outcome data in clinical trials: a comparison of five estimators. Journal of biopharmaceutical statistics, 29(2). pp. 400–410. 10.1080/10543406.2018.1559852 Retrieved from https://hdl.handle.net/10161/18194.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Chow

Shein-Chung Chow

Professor of Biostatistics & Bioinformatics

My research interest includes statistical methodology development and application in the area of biopharmaceutical/clinical statistics such as bioavailability and bioequivalence, clinical trials, bridging studies, medical devices, and translational research/medicine. Most recently, I am interested in statistical methodology development for the use of adaptive design methods in clinical trials and methodology development for assessment of biosimilarity of follow-on biologics. In addition, I am also interested in methodology development for statistical evaluation of traditional Chinese medicine (TCM) clinical trials.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.